Sign In
Buy PDSB
$0.735
+0.0237 (+3.33%)
At Close: Jul 17, 2026
PDS Biotechnology Announces Details of Virtual KOL Event
08:00am, Friday, 03'rd May 2024
Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 Virtual Webinar Updated
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
08:00am, Thursday, 02'nd May 2024
PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
12:17pm, Wednesday, 27'th Mar 2024
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
07:30am, Wednesday, 27'th Mar 2024
Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
08:00am, Wednesday, 20'th Mar 2024
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing p
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
10:55am, Wednesday, 13'th Mar 2024
Biotech stocks are not for investors with a low-risk tolerance. This sector has stocks that are either considered blue-chip names or pre-revenue lotto tickets.
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
08:00am, Wednesday, 13'th Mar 2024
Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants
PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data
06:59pm, Friday, 26'th Jan 2024
Preliminary efficacy results from phase 1/2 Mayo Clinic study, using PDS0101 + KEYTRUDA to treat patients with Oropharyngeal cancer, expected in Q2 2024. The global oral cancer treatment market is exp
PDS Biotech Announces Retirement of Lauren V. Wood, M.D.
04:45pm, Monday, 22'nd Jan 2024
Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company Board-certified oncologist and hemat
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
08:00am, Tuesday, 16'th Jan 2024
PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pi
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
01:32pm, Tuesday, 02'nd Jan 2024
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:50pm, Monday, 04'th Dec 2023
PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeli
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
07:30am, Tuesday, 28'th Nov 2023
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pi
PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript
12:17pm, Tuesday, 14'th Nov 2023
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Nicole Jones - Investor Relations Frank Bedu-Addo - Chief Executive Offi
